Avandia and Actos, both type 2 diabetes drugs, have recently made news headlines again for declining sales and status because of serious risks associated with consumption of the drugs.The article found that by 2011 Avandia, a type 2 diabetes non-insulin treatment, will see a decrease in sales because of the continued cloud of controversy shrouding the drug’s effects and linking the drug to early onset osteoporosis and increased risk of heart failure among patients.What Does Avandia Treat?Part of the glitzaone drug class, Avandia (rosiglitazone maleate) is an anti-diabetic treatment. The type 2 diabetes drug was released from GlaxoSmithKline in mid-1999 and has since been prescribed to millions of diabetic patients. Diabetics must be sure to avoid going into diabetic shock, which can be fatal and Avandia works to control natural levels of insulin to avoid this.The dangers of Avandia began to be reported by 2007. One article, published in the New England Journal of Medicine linked the anti-diabetic drug to an increased risk of heart disease and heart failure among patients.An additional study conducted by Swiss researchers found that patients consuming the diabetic drug were more likely to suffer from bone fractures and breaks because of accelerated osteoporosis that was […]

Full Article At: KnowHow-Now.com Articles

Bookmark to: